Physician profile
Robert L Andersen
NPI 1083647812
$2,653.10
in general payments reported to CMS, 2019-2025
33 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $920 · 2020: $173 · 2021: $212 · 2022: $1,018 · 2023: $331.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $331.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $330.80 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $451.96 | 2019-2023 | Rybelsus, Ozempic, Wegovy |
| Astrazeneca Pharmaceuticals Lp | $439.24 | 2019-2023 | Farxiga, Fasenra |
| Glaxosmithkline, LLC. | $252.65 | 2019-2022 | |
| Pfizer INC. | $144.92 | 2019-2023 | |
| Merck Sharp & Dohme LLC | $143.54 | 2019-2022 | |
| Amarin Pharma, INC. | $132.32 | 2019-2022 | |
| Lilly USA, LLC | $128.78 | 2020-2023 | Emgality, Jardiance, Mounjaro |
| Boehringer Ingelheim Pharmaceuticals, INC. | $124.66 | 2019-2022 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $76.91 | 2022 | |
| Novartis Pharmaceuticals Corporation | $76.88 | 2019-2021 | |
| Upsher-Smith Laboratories LLC | $72.97 | 2022 | |
| Abbvie INC. | $60.66 | 2022 | |
| Amgen INC. | $55.25 | 2019-2022 | |
| Abbott Laboratories | $54.88 | 2019-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $47.30 | 2021-2023 | Trintellix |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exact Sciences Corporation | $45.13 | 2023 | Cologuard Collection Kit |
| Esperion Therapeutics, INC. | $41.59 | 2022 | |
| Astellas Pharma US INC | $29.94 | 2021-2022 | |
| Sanofi-Aventis U.S. LLC | $26.97 | 2019-2022 | |
| Sanofi Pasteur INC. | $24.28 | 2019-2020 | |
| Idorsia Pharmaceuticals US INC | $20.35 | 2022 | |
| Genentech USA, INC. | $19.92 | 2019 | |
| Nestle Healthcare Nutrition INC. | $19.67 | 2020 | |
| Celgene Corporation | $19.05 | 2019 | |
| Janssen Pharmaceuticals, INC | $18.67 | 2022 | |
| Axsome Therapeutics, INC. | $18.59 | 2023 | Auvelity |
| Jazz Pharmaceuticals INC. | $17.63 | 2021 | |
| Antares Pharma, INC. | $17.31 | 2023 | Xyosted, Tlando, Nocdurna |
| Alfasigma USA, INC. | $15.33 | 2021 | |
| Collegium Pharmaceutical, INC. | $15.18 | 2022 | |
| Shire North American Group INC | $14.25 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $13.96 | 2021 | |
| Adlon Therapeutics L.P. | $12.36 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Andersen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.